Business Wire

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 percent in adults with and without diabetes who had heart ...

INGELHEIM, Germany and INDIANAPOLIS--(BUSINESS WIRE)--Full results from the EMPEROR-Reduced Phase III trial in adults with heart failure with reduced ejection fraction, with and without diabetes, ...
Monthly Prescribing Reference

Empagliflozin Benefits Patients With Heart Failure and Preserved Ejection Fraction

Lungs Heart The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes. Full results from the phase 3 ...
Nasdaq

Jardiance® reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25% in adults with and without diabetes who had heart failure ...

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 29, 2020/ PRNewswire/-- Full results from the EMPEROR-Reduced phase III trial in adults with heart failure with reduced ejection fraction, with and without ...